As of 2026-10-02, the EV/EBITDA ratio of Theravance Biopharma Inc (TBPH) is 95.42. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TBPH's latest enterprise value is 627.36 mil USD. TBPH's TTM EBITDA according to its financial statements is 6.58 mil USD. Dividing these 2 quantities gives us the above TBPH EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 7.2x - 9.9x | 8.8x |
| Forward P/E multiples | 9.6x - 14.1x | 11.8x |
| Fair Price | 5.84 - 19.22 | 11.46 |
| Upside | -65.7% - 12.9% | -32.7% |
| Date | EV/EBITDA |
| 2026-09-23 | 95.42 |
| 2026-09-22 | 95.42 |
| 2026-09-21 | 95.57 |
| 2026-09-18 | 95.34 |
| 2026-09-17 | 95.49 |
| 2026-09-16 | 95.42 |
| 2026-09-15 | 95.49 |
| 2026-09-14 | 95.42 |
| 2026-09-11 | 95.26 |
| 2026-09-10 | 95.34 |
| 2026-09-09 | 95.65 |
| 2026-09-08 | 95.65 |
| 2026-09-04 | 95.81 |
| 2026-09-03 | 95.81 |
| 2026-09-02 | 95.73 |
| 2026-09-01 | 95.42 |
| 2026-08-31 | 95.49 |
| 2026-08-28 | 95.57 |
| 2026-08-27 | 95.49 |
| 2026-08-26 | 95.42 |
| 2026-08-25 | 95.42 |
| 2026-08-24 | 95.26 |
| 2026-08-21 | 95.26 |
| 2026-08-20 | 94.79 |
| 2026-08-19 | 95.10 |
| 2026-08-18 | 94.79 |
| 2026-08-17 | 94.55 |
| 2026-08-14 | 94.94 |
| 2026-08-13 | 94.55 |
| 2026-08-12 | 94.55 |
| 2026-08-11 | 94.55 |
| 2026-08-10 | 94.47 |
| 2026-08-07 | 94.63 |
| 2026-08-06 | 94.55 |
| 2026-08-05 | 94.39 |
| 2026-08-04 | 94.23 |
| 2026-08-03 | 94.15 |
| 2026-07-31 | 94.08 |
| 2026-07-30 | 94.00 |
| 2026-07-29 | 94.00 |
| 2026-07-28 | 94.31 |
| 2026-07-27 | 94.08 |
| 2026-07-24 | 94.08 |
| 2026-07-23 | 94.08 |
| 2026-07-22 | 93.68 |
| 2026-07-21 | 93.92 |
| 2026-07-20 | 93.68 |
| 2026-07-17 | 94.63 |
| 2026-07-16 | 94.94 |
| 2026-07-15 | 94.63 |